Non‐ICANS neurotoxicity after BCMA‐directed CAR‐T therapy: Clinical spectrum, outcomes, and a framework for neurology–oncology co‐management

Jan‐Michael Werner, Philipp Gödel, Norbert Galldiks, Christopher Krone, Michael Schroeter, Udo Holtick, Ruth Flümann, Gilbert Wunderlich, Michael Hallek, Gereon R. Fink, Christoph Scheid, Oezguer A. Onur, Tim Richardson

Open source

DOI
10.1002/hem3.70404
Published
2026-06
Container
HemaSphere
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/hem3.70404,
  title = {Non‐ICANS neurotoxicity after BCMA‐directed CAR‐T therapy: Clinical spectrum, outcomes, and a framework for neurology–oncology co‐management},
  author = {Jan‐Michael Werner and Philipp Gödel and Norbert Galldiks and Christopher Krone and Michael Schroeter and Udo Holtick and Ruth Flümann and Gilbert Wunderlich and Michael Hallek and Gereon R. Fink and Christoph Scheid and Oezguer A. Onur and Tim Richardson},
  year = {2026},
  journal = {HemaSphere},
  doi = {10.1002/hem3.70404},
  url = {https://doi.org/10.1002/hem3.70404}
}

RIS

TY  - JOUR
TI  - Non‐ICANS neurotoxicity after BCMA‐directed CAR‐T therapy: Clinical spectrum, outcomes, and a framework for neurology–oncology co‐management
AU  - Jan‐Michael Werner
AU  - Philipp Gödel
AU  - Norbert Galldiks
AU  - Christopher Krone
AU  - Michael Schroeter
AU  - Udo Holtick
AU  - Ruth Flümann
AU  - Gilbert Wunderlich
AU  - Michael Hallek
AU  - Gereon R. Fink
AU  - Christoph Scheid
AU  - Oezguer A. Onur
AU  - Tim Richardson
PY  - 2026
JO  - HemaSphere
DO  - 10.1002/hem3.70404
UR  - https://doi.org/10.1002/hem3.70404
ER  - 

APA

Werner, J., Gödel, P., Galldiks, N., Krone, C., Schroeter, M., Holtick, U., Flümann, R., Wunderlich, G., Hallek, M., Fink, G. R., Scheid, C., Onur, O. A., & Richardson, T. (2026). Non‐ICANS neurotoxicity after BCMA‐directed CAR‐T therapy: Clinical spectrum, outcomes, and a framework for neurology–oncology co‐management. HemaSphere. https://doi.org/10.1002/hem3.70404

Source records